In this webcast, the valuation, investigation, financing and restructuring experts from Kroll China analyzed the current situation from different angles and discuss coping strategies and solutions.
Watch the Webcast Replay here.
Key Topics
- Latest development of discussion between PCAOB and CSRC and what are the implications to the Chinese companies listed in the US
- What strategic options that board of director can consider if PCAOB and CSRC cannot reach consensus (e.g. delisting and then relisting in Hong Kong, M&A etc.)?
- What are procedures that the boards have to carry out to fulfill their fiduciary duty and manage legal risks?
- What are the strategic options that existing investors can consider?
- Why financial distress (operation mismanagement and/or poor corporate governance and compliance) can lead to delisting risks?
- How can corporate restructuring assist Chinese companies listed on the U.S. exchanges to overcome challenges in the current difficult market situations?
- How to protect the listed companies from winding up petitions? And work with institutional creditors?
- How to protect investors? What strategic options for investors of listed Chinese American Depositary Receipts (ADR) or bond holders in financial distress during the process of being delisted?
- What are the potential opportunities for new investors?
Please submit the form to download the webcast slides.
